LAU-DP-11

LAU-DP-11 is an investigational drug candidate being developed by Vectans Pharma for the treatment or supportive care of *Clostridioides difficile* infection (CDI). The candidate utilizes the proprietary Lauriad technology, which is a muco-adhesive formulation platform designed to provide sustained release and high local concentrations of an active ingredient. While the Lauriad platform is traditionally associated with buccal delivery for oral infections or systemic absorption, LAU-DP-11 represents an application of this technology for gastrointestinal indications. The specific active pharmaceutical ingredient (API) and its exact molecular target have not been publicly disclosed by the company, and the program is currently in the early stages of development.